bibliographicCitation |
Arellano J, Leteneux C, Kotowa W, Gatzemeier U, Pirk O, Gabriel A, Heigener D. Comment and Reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective. Journal of Medical Economics. 2008 Jan;11(2):363–70. doi: 10.3111/13696990802113147. |